ALNYLAM PHARMACEUTICALS, INC. ALNY

Alnylam Pharmaceuticals is not in the business of selling hope in vials; it sells silence-gene silence-using RNA interference technology that turns off the scripts written by faulty genes, and the FDA finally approved its first transthyretin amyloidosis cardiomyopathy drug, AMVUTTRA, in March 2025. By the first quarter of 2026, the company’s net product revenues were already dominated by TTR products, with AMVUTTRA driving the bus, while the cost of goods sold climbed to 20% of net product revenues, a margin squeeze that suggests the royalty spigot is now wide open and the bill for R&D hasn’t been folded into the price tag just yet.

What Alnylam actually does is design double-stranded RNA molecules that hijack the cell’s own machinery to block the production of disease-causing proteins, a feat of molecular aikido that has earned it the label ‘the leading RNAi therapeutics company’ on its own website. The platform is elegant, the science is peer-reviewed, and the pipeline stretches from rare liver diseases to genetic angioedema, but elegance does not pay the rent when the royalty cheque is sliced thinner each quarter by rising COGS and the company’s $1.32 billion R&D bill continues to outpace its net income.

According to the 2025 10-K, Alnylam closed the year with $3.71 billion in revenue, $313.7 million in net income, and a diluted EPS of $2.33, all figures that look healthier than the balance sheet’s $789.2 million in shareholders’ equity, a number that is roughly the cost of a single mid-sized biotech acquisition. Cash and equivalents stood at $1.66 billion, but $1.36 billion of that is spoken for by royalty obligations, leaving the company with liquidity that would comfortably fund a three-year sabbatical for every employee rather than a single bolt-on acquisition. Operating income was $501.6 million, a figure that sounds robust until you divide it by the $1.32 billion R&D line and realise the company is spending more on discovery than it earns from operations.

Inventory net rose to $82.7 million at year-end 2025, but the 10-Q for Q1 2026 shows a sequential $8.5 million drawdown, a move that could indicate supply-chain optimisation-or simply that the company is shifting product to distributors faster than patients can swallow the pills. Meanwhile, the 8-K filed on 30 April 2026 confirms management’s expectation that COGS as a percentage of net product revenues will rise further in 2026, primarily because AMVUTTRA sales are climbing and the royalty rate is creeping upward like a landlord in a tight market. The same filing admits that a ‘significant portion’ of revenue in 2025 and Q1 2026 came from TTR products, a dependency that would make any portfolio manager nervous if the patent clock were ticking faster than the clinical data.

The week of 1 June 2026 saw a flurry of insider filings-Forms 3, 4, and a 144 for 1.3 million shares-activity that is neither illegal nor unusual but does invite questions about whether the stock’s recent momentum is being met with equally recent selling. The company’s own investor-relations page confirms the RNAi platform and its promise of ‘positive impact on the world,’ a mission statement that sounds noble until you price the noble part at $3.71 billion in revenue and $313.7 million in profit. The evidence rail does not include analyst valuation commentary or forward-looking statements beyond management’s COGS warning, so the file ends where the filings begin.

For a deeper look at the mechanics behind AMVUTTRA’s approval and its impact on the 2025 revenue mix, see the 8-K dated 27 May 2026 and the 10-Q for the quarter ended 31 March 2026, both filed on the SEC EDGAR system. The company’s official site provides background on the RNAi platform, while the SEC submissions JSON offers a full catalogue of filings, but neither source supplies quarterly cash-flow surprises or pipeline inflection points beyond what is already on the public record. If you want to know how the royalty waterfall is flowing, you’ll need to parse the 10-K’s revenue recognition footnote; if you want to know whether insiders are quietly hedging, the Forms 4 and 144 for early June are your best bet.